Coloplast stock falls after JPMorgan cuts price target and rating

Published on 09/10/2026 at 15:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coloplast stock slipped on Nasdaq Copenhagen after JPMorgan on September 9, 2026 cut its rating to Underweight and lowered the December 2027 price target to DKK 377 from DKK 484. The move comes as investors weigh margin pressure and valuation risks highlighted in recent coverage.

Reinraum-Produktion medizinischer Versorgungsprodukte in heller Fertigungshalle — Coloplast A/S (DK0060448595) zeigt hier moderne sterile Produktion medizinischer Versorgungsprodukte in heller Fertigungshalle, Illustration mit AI erstellt.

Coloplast stock (ISIN DK0060448595) came under pressure on Nasdaq Copenhagen on September 9, 2026 after a sharp analyst downgrade from JPMorgan, which lowered its December 2027 price target to DKK 377 from DKK 484 and moved the shares to Underweight from Neutral, a cut of about 22 percent that immediately fed into trading sentiment according to Investing.com.

JPMorgan downgrade hits valuation

According to Investing.com on September 9, 2026, Coloplast stock fell around 3.3 percent during the session to trade near DKK 431.90, with an intraday low of DKK 427.80 as investors digested the downgrade and lower price target.

The same report states that JPMorgan cut its December 2027 price target from DKK 484 to DKK 377, implying a reduction of roughly 22 percent and signaling a more cautious stance on the company’s valuation and earnings trajectory over the medium term, which has sharpened concerns among shareholders about how quickly margins can recoverInvesting.com.

Margin pressure and strategic uncertainty

As Investing.com reports, JPMorgan’s move crystallized existing worries about margin pressure in Coloplast’s core business and about strategic uncertainty ahead of a planned guidance update in November 2026, with the downgrade described as a decisive trigger that brought these issues to the forefront of investor discussions.

The analysis highlights that Coloplast is facing a period in which higher input costs and investments in growth initiatives weigh on profitability, and the bank’s Underweight rating reflects a view that the risk-reward balance has turned less favorable until clearer visibility emerges on how management intends to defend margins and deliver on its long-term growth ambitionsInvesting.com.

Stock level and investor perspective

On Nasdaq Copenhagen, Coloplast’s share price around DKK 431.90 as of September 9, 2026 places the stock below the revised December 2027 price target of DKK 377 in terms of downside implied by JPMorgan’s view, underscoring that the bank sees further room for weakness compared with the current market level.